Evidence map›Paper›PMID 42591319›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Biomarkers for Alzheimer's disease to differentiate normal, SCD, and MCI subjects and their correlation with cognitive function.

Allal Boutajangout, Ricardo S Osorio, Arjun V Masurkar, Ludovic Debure, Mobeena Ghuman, Wajiha Ahmed, Elizabeth Pirraglia, Alok Vedvyas, Jon Links, Brianna Vega and 4 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Allal BoutajangoutAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Ricardo S OsorioAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Arjun V MasurkarAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Ludovic DebureAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Mobeena GhumanAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Wajiha AhmedAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Elizabeth PirragliaDepartment of Population Health NYU Grossman School of Medicine New York New York USA.
Alok VedvyasAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Jon LinksAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Brianna VegaAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Karyn MarshAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Joshua ChodoshAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.
Yongzhao ShaoDepartment of Population Health NYU Grossman School of Medicine New York New York USA.
Thomas WisniewskiAlzheimer's Disease Research Center and Center for Cognitive Neurology New York New York USA.ORCID https://orcid.org/0000-0002-3379-8966

Funding

Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Mary Sherman Mittelman · 2020 to 2026
$28.4M
Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 InfectionR01AG077422 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jennifer Ann Frontera, Yulin Ge · 2022 to 2026
$6.9M
Multi-scale and multi-modality imaging of neuropathology in VCIDU24NS135568 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JAMES C GEE, Yulin Ge · 2023 to 2026
$6.6M
NIA NIH HHS P30 AG066512NIA NIH HHS R01 AG077422NINDS NIH HHS U24 NS135568NIOSH CDC HHS U01 OH012486
6 · The paper itself

Abstract

introductionWe assessed plasma biomarkers for the diagnosis of early Alzheimer's disease (AD).

methodsSubjects were divided into three groups: cognitively unimpaired (CU) (without subjective cognitive decline [SCD]) (

resultsBiomarker levels were regressed by cognitive group, age, sex, race, and apolipoprotein E apoE ε4 status, yielded significant positive associations between age and numerous AD, neuroinflammation, cytokine, and BBB plasma markers. DISCUSSION: Linear regression analysis, adjusted for age, sex, race, and ApoE status, revealed significant differences between cognitive groups in levels of several plasma biomarkers and associations with age and sex. Neuroinflammation and BBB dysfunction showed significant positive associations with age across different stages of AD.

Indexed as

Alzheimer's diseaseBBB dysfunctionbiomarkerscytokinesmild cognitive impairmentplasmasubjective cognitive decline

Identifiers

PMID42591319
PMCPMC13461772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.